• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary therapy. >Patients’ and Healthcare Professionals’ Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801?mg Tablet Formulation: A Multinational Survey
【24h】

Patients’ and Healthcare Professionals’ Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801?mg Tablet Formulation: A Multinational Survey

机译：患者和医疗保健专业人员用Pirfenidone 801的特发性肺纤维化处理的经验吗？MG片剂制剂：跨国调查

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionIdiopathic pulmonary fibrosis (IPF) is a progressive, debilitating interstitial lung disease. Two antifibrotics, pirfenidone and nintedanib, are available for IPF treatment. Pirfenidone is available as 267?mg capsules and, more recently, as 267?mg and 801?mg tablets. The aim of this study was to examine the perceived benefits of the 801?mg formulation on patient quality of life (QoL), IPF management and pill burden.MethodsForty-seven patients with IPF and 170 healthcare professionals (HCPs; 150 physicians in France, Germany, Spain and the USA and 20?nurses in the USA) completed online questionnaires comprising 67 and 61 questions, respectively. Eligible patients had experience switching from the 267?mg pirfenidone tablet or capsule formulations to the 801?mg tablet formulation, and eligible HCPs were experienced in managing this switch. Questions included single and multiple responses and scalar questions with responses on a 7-point Likert scale.ResultsPatients received the 267?mg formulation for a median (range) of 6.0?(2.0–40.0) months prior to switching to the 801?mg formulation. Higher percentages of patients reported satisfaction with the 801?mg versus the 267?mg formulation for its convenience (64 vs. 17%) and number of dosage units (70 vs. 2%). More patients reported good emotional well-being on the 801?mg versus the 267?mg formulation (51 vs. 21%), and fewer patients reported missing a dose of pirfenidone (21 vs. 30%). More HCPs perceived high patient adherence with the 801?mg versus the 267?mg formulation (57 vs. 37%). Overall, 33% of physicians had experienced switching patients back to the 267?mg formulation.ConclusionPatients and HCPs consistently favoured the 801?mg formulation across multiple domains, including convenience, patient QoL and adherence. The 801?mg formulation may provide an alternative to the 267?mg formulation in patients established on the recommended daily dose of pirfenidone.
机译：介导的肺纤维化（IPF）是一种进步，令人衰弱的间质性肺病。两种抗灰度，Pirfenidone和尼林尼布可用于IPF治疗。 Pirefenidone可作为267？Mg胶囊提供，最近，最近，为267毫克和801毫克片剂。本研究的目的是探讨801毫克制定的患者生活质量（QOL），IPF管理和药丸负担的感知益处。方法幸福 - 七名IPF和170名医疗保健专业人员（HCPS;法国150名医生，德国，西班牙和美国和20岁的美国人）在美国完成了在线问卷，分别包括67和61个问题。符合条件的患者在267毫克镁吡啶酮片或胶囊配方中切换到801？Mg片剂配方，并且在管理此开关时经历了合格的HCP。问题包括单一和多个响应和标量题，并在7分Likert Scale.Resultspatients接收到6.0的中位数（范围）的267？MG配方？（2.0-40.0）在切换到801？MG制剂之前。较高百分比的患者报告的801毫克与267毫克相比，其方便（64 vs.17％）和剂量单位数（70 vs.2％）。更多患者报告了801毫克的良好情绪福祉与267毫克（51毫克）（51毫升）（51 vs.21％），并且报告的患者缺少一剂Pirfenidone（21 vs.30％）。更多HCP感知高患者粘附与801Ωmg与267毫克配方（57对37％）。总体而言，33％的医生经历过切换患者返回267毫克配方。结论韧性和HCPS始终如一地支持跨多个域的801？MG配方，包括方便，患者QOL和遵守。 801？Mg制剂可以提供267毫克制剂的替代方案，在建议的每日服用的Pirfenidone的患者中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号